XML 118 R103.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2024
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]              
Revenue $ 5,367 $ 11,766 $ 9,386 $ 21,152 $ 26,519 $ 32,110 $ 53,467
Cost of revenue 2,256 2,773 2,520 5,293 7,549 10,607 11,970
Gross profit 3,111 8,993 6,866 15,859 18,970 21,503 41,497
Operating expenses:              
Sales and marketing 5,197 6,718 6,145 12,863 18,060 25,933 46,857
Research and development 3,212 4,310 5,725 10,035 13,247 17,369 27,694
General and administrative 7,043 7,311 6,386 13,697 20,746 28,399 46,024
Total operating expenses: 15,452 18,339 18,256 36,595 52,053 71,701 120,575
Loss from operations (12,341) (9,346) (11,390) (20,736) (33,083) (50,198) (79,078)
Other segment items           43,000 (3,739)
Net loss $ 8,736 $ (8,322) $ 1,996 $ (6,326) $ 2,410 (7,198) (82,817)
Clinical Trials and Medical Affairs              
Operating expenses:              
Research and development           9,455 15,700
Product Development              
Operating expenses:              
Research and development           3,190 4,477
Digital              
Operating expenses:              
Research and development           2,379 4,451
Quality and Regulatory              
Operating expenses:              
Research and development           $ 2,345 $ 3,066